Literature DB >> 23507309

Design of synthetic autonomous VH domain libraries and structural analysis of a VH domain bound to vascular endothelial growth factor.

Xiaolei Ma1, Pierre A Barthelemy, Lionel Rouge, Christian Wiesmann, Sachdev S Sidhu.   

Abstract

We compared the capacity of an autonomous heavy chain variable (VH) domain (VH-B1a) to support diversity within its antigen-binding site relative to the conventional antigen-binding fragment (Fab) from which it was derived. We find that VH-B1a can tolerate significant diversity within all three complementarity-determining regions (CDRs) and also within framework 3, and thus, VH-B1a and the Fab are similar in terms of the regions of the antigen-binding site that can tolerate diversity without compromising stability. We constructed libraries of synthetic VH domains and isolated binders with moderate affinity for vascular endothelial growth factor (VEGF) from a library in which only CDR3 was randomized. One binder was subjected to affinity maturation to derive an autonomous VH domain (VH-V1a) that recognized both human and mouse VEGF with high affinity (KD=16nM or 10nM, respectively). Structural analysis revealed that VH-V1a binds to an epitope that is distinct from the epitopes of a natural VEGF receptor and six different anti-VEGF Fabs. Moreover, VH-V1a recognizes VEGF by using an unusual paratope consisting predominantly of CDR3 but with significant contributions from framework residues within the former light chain interface. These results suggest that VH-B1a and other autonomous VH domains may be useful scaffolds to support both conventional libraries with antigen-binding sites built from the three CDR loops and, also, nonconventional libraries with antigen-binding sites built from CDR3 and the former light chain interface.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23507309     DOI: 10.1016/j.jmb.2013.03.020

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  13 in total

1.  Fully Human VH Single Domains That Rival the Stability and Cleft Recognition of Camelid Antibodies.

Authors:  Romain Rouet; Kip Dudgeon; Mary Christie; David Langley; Daniel Christ
Journal:  J Biol Chem       Date:  2015-03-03       Impact factor: 5.157

2.  Development of a novel peptide aptamer that interacts with the eIF4E capped-mRNA binding site using peptide epitope linker evolution (PELE).

Authors:  Yuri Frosi; Simon Ng; Yen-Chu Lin; Shimin Jiang; Siti Radhiah Ramlan; Dilraj Lama; Chandra S Verma; Ignacio Asial; Christopher J Brown
Journal:  RSC Chem Biol       Date:  2022-05-19

Review 3.  Engineered Autonomous Human Variable Domains.

Authors:  Johan Nilvebrant; Peter M Tessier; Sachdev S Sidhu
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

4.  A T cell redirection platform for co-targeting dual antigens on solid tumors.

Authors:  Leonie Enderle; Karim H Shalaby; Maryna Gorelik; Alexander Weiss; Levi L Blazer; Marcin Paduch; Lia Cardarelli; Anthony Kossiakoff; Jarrett J Adams; Sachdev S Sidhu
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

5.  A highly functional synthetic phage display library containing over 40 billion human antibody clones.

Authors:  Marcel Weber; Emil Bujak; Alessia Putelli; Alessandra Villa; Mattia Matasci; Laura Gualandi; Teresa Hemmerle; Sarah Wulhfard; Dario Neri
Journal:  PLoS One       Date:  2014-06-20       Impact factor: 3.240

6.  Molecular dynamics simulations and docking enable to explore the biophysical factors controlling the yields of engineered nanobodies.

Authors:  Miguel A Soler; Ario de Marco; Sara Fortuna
Journal:  Sci Rep       Date:  2016-10-10       Impact factor: 4.379

7.  Efficient affinity maturation of antibody variable domains requires co-selection of compensatory mutations to maintain thermodynamic stability.

Authors:  Mark C Julian; Lijuan Li; Shekhar Garde; Rebecca Wilen; Peter M Tessier
Journal:  Sci Rep       Date:  2017-03-28       Impact factor: 4.379

Review 8.  Nanobodies: Chemical Functionalization Strategies and Intracellular Applications.

Authors:  Dominik Schumacher; Jonas Helma; Anselm F L Schneider; Heinrich Leonhardt; Christian P R Hackenberger
Journal:  Angew Chem Int Ed Engl       Date:  2018-01-26       Impact factor: 15.336

9.  Antibody light chain variable domains and their biophysically improved versions for human immunotherapy.

Authors:  Dae Young Kim; Rebecca To; Hiba Kandalaft; Wen Ding; Henk van Faassen; Yan Luo; Joseph D Schrag; Nadereh St-Amant; Mary Hefford; Tomoko Hirama; John F Kelly; Roger MacKenzie; Jamshid Tanha
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

10.  Stability-Diversity Tradeoffs Impose Fundamental Constraints on Selection of Synthetic Human VH/VL Single-Domain Antibodies from In Vitro Display Libraries.

Authors:  Kevin A Henry; Dae Young Kim; Hiba Kandalaft; Michael J Lowden; Qingling Yang; Joseph D Schrag; Greg Hussack; C Roger MacKenzie; Jamshid Tanha
Journal:  Front Immunol       Date:  2017-12-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.